Our Latest Data

Event
IDWeek Los Angeles, CA \| October 2024 CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza [Poster] [Rapid Fire]
OPTIONS XII for the Control of Influenza Brisbane, Australia \| September 2024 Safety Data from Phase 1 and Phase 2a Studies of CD388, a Drug Fc-conjugate for Seasonal Pan-Influenza Prophylaxis Pharmacokinetics and Safety of CD388 Following Subcutaneous Administration in Healthy Japanese Participants
ASM MICROBE Atlanta, GA \| June 2024 Comparison of Different Allometric Scaling Approaches to Project Human Pharmacokinetics (PK) of CD388, a Novel Drug-Fc Conjugate, in Development for Influenza Prevention
Manuscript CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase bioRxiv \| June 2024
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Barcelona, Spain \| April 2024 Prophylactic efficacy of CD388, a novel drug-Fc conjugate (DFC), in an influenza A/H3N2 human challenge model CD388, a drug-Fc conjugate, shows long half-life in early clinical studies
American Association for Cancer Research (AACR) Annual Meeting San Diego, CA \| April 2024 Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization
ESMO Immuno-Oncology (IO) Annual Congress Geneva, Switzerland \| December 2023 Discovery of a Novel, Dual CD73 & PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer [Poster] [Abstract] Discovery of CBO421, a First-in-Class Drug Fc-Conjugate (DFC), Targeting CD73 in Cancer [Poster] [Abstract]
Society for Immunotherapy of Cancer (SITC) San Diego, CA \| November 2023 Discovery of CBO421, a First-in-Class Drug Fc-conjugate (DFC), Targeting CD73 in Cancer [Poster] [Abstract]
IDWeek Boston, MA \| October 2023 Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), is Driven by the Small Molecule Neuraminidase Inhibitor (NAI) In Vivo Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), Against Seasonal Subtypes of Influenza in Prophylaxis in Immune Competent Mice, and in a Severe Immunodeficient (SCID) Mouse Model Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza [2514]
Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit Boston, MA \| June 2023 Cidara Drug-Fc-Conjugates (DFCs): A New Approach to Treatment of Cancer
International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Seattle, WA \| May 2023 CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates Potent, Universal Activity Against Influenza A and B CD388 Demonstrates a High Barrier to Resistance and Retains Potent Activity Against NAI Influenza A and B
ESMO Targeted Anticancer Therapies Paris, France \| March 2023 Discovery of CBO-212, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
ESWI Keynote Lecture \| December 2020 Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak^® Influenza Antiviral Conjugates (AVCs)
ESWI VIRTUAL \| December 2020 In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI) [139] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, by Multiple Dosing Routes Against Influenza A (H1N1), and Activity Against Oseltamivir-Resistant Isolates in Lethal Mouse Models [159] Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains [269]
IDWeek VIRTUAL \| October 2020 Efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models [159] CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models [162] Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models [1276] New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single [1283]
ECCMID Abstract Book \| April 2020 Preclinical Efficacy, Pharmacokinetics, and Safety of CD377, a Novel Antiviral Fc-Conjugate Against Influenza [Abstract 5126] CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Superior Reduction of Viral Burden and Cytokine Levels Compared to Oseltamivir in a Lethal Mouse Model of Influenza A (H1N1) Infection [Abstract 8839] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Seasonal Influenza in Lethal Mouse Models [Abstract 5793] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Influenza A (H1N1) in a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID) [Abstract 6009] CD377, a Novel Antiviral Fc-Conjugate, Demonstrates a Lower Resistance Potential than Baloxavir and Oseltamivir against Pandemic Influenza A/H1N1 [Abstract 5707] CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Potent Broad-Spectrum Activity in Multiple in vitro Assays Against Influenza A and B [Abstract 8832] Fc-Mediated Fcγ Receptor Engagement of CD377, a Novel Antiviral Fc-Conjugate, Translates Into Potent ADCP and ADCC Activity [Abstract 8820]
Manuscript Antivirals Targeting the Neuraminidase Cold Spring Harb Perspect Med \| March 2020
IDWeek Washington, D.C. \| October 2019 Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria) [689]
Options X Singapore \| August 2019 Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, against Influenza A (H1N1) In a Lethal Mouse Model of Severe Combined Immunodeficiency (SCID) [11760] Preclinical Efficacy, Pharmacokinetics, and Safety of CB-012, A Novel Antiviral Fc-Conjugate against Influenza [10973] Novel Antiviral Fc-Conjugate CB-012 Demonstrates Potent Activity in Cytopathic Effect (CPE) and Viral Growth Inhibition Assays against Influenza A and B Strains [10974] Efficacy of CB-012, A Novel Antiviral Fc-Conjugate, in Lethal Mouse Models of Oseltamivir-Sensitive and -Resistant Influenza A H1N1 and H3N2 Isolates [10979] Fc-Mediated Effector Function Contributes to Potency of Novel Antiviral Fc-Conjugate CB-012 [11094]
ASM Microbe San Francisco, CA \| June 2019 CB-012 – A Novel Antiviral-Fc Conjugate for Treatment and Prevention of Influenza Virus [SUNDAY – HMB-385]
ECCMID Amsterdam \| April 2019 Cloudbreak: A Novel Approach for the Treatment and Prevention of Influenza Virus [O0818]

Our Latest Data

IDWeek

OPTIONS XII for the Control of Influenza

ASM MICROBE

Manuscript

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

American Association for Cancer Research (AACR) Annual Meeting

ESMO Immuno-Oncology (IO) Annual Congress

Society for Immunotherapy of Cancer (SITC)

IDWeek

Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit

International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)

ESMO Targeted Anticancer Therapies

ESWI

ESWI

IDWeek

ECCMID

Manuscript

IDWeek

Options X

ASM Microbe

ECCMID

Contact Us

Subscribe